Literature DB >> 1505200

The effects of 5-fluorouracil and mitomycin C on the corneal endothelium.

R M Nuyts1, E Pels, E L Greve.   

Abstract

5-Fluorouracil (5-FU) and Mitomycin C (MMC) are used as adjunct chemotherapy during glaucoma filtering surgery to suppress conjunctival fibroblast proliferation. Since part of these agents may gain access to the anterior chamber and cause cytotoxicity to the corneal endothelium we set up an in vitro system to establish a dose-response effect. Cytotoxicity of MMC and 5-FU was quantified using Mosmann's colorimetric assay in a bovine endothelial cell culture system. In this assay the respiratory activity of the cells is used as a marker for cell viability. After incubation for 5 minutes the 3.0 mg/ml concentration of MMC showed endothelial cytotoxicity, whereas no endothelial toxicity of 5-FU was noted in concentrations up to 50 mg/ml. After incubation for 30 minutes endothelial cytotoxicity was demonstrated for 50 mg/ml of 5-FU and 1 mg/ml of MMC. After an exposure-time of 60 minutes the toxicity level remained 50 mg/ml for 5-FU but decreased to 0.5 mg/ml for MMC. We conclude that with respect to the clinically used concentrations and methods of application of 5-FU and MMC in vivo endothelial toxicity is not to be expected. However, in cases of accidental access of MMC to the anterior eye chamber and following a reduction of aqueous turnover rate the safety of MMC is unwarranted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505200     DOI: 10.3109/02713689209001812

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  15 in total

1.  Efficacy and safety of mitomycin C as an agent to treat corneal scarring in horses using an in vitro model.

Authors:  Dylan G Buss; Ajay Sharma; Elizabeth A Giuliano; Rajiv R Mohan
Journal:  Vet Ophthalmol       Date:  2010-07       Impact factor: 1.644

2.  Trypan blue identifies antimetabolite treatment area in trabeculectomy.

Authors:  P R Healey; J G Crowston
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Snailtrack corneal changes following subconjunctival injection of 5-fluorouracil.

Authors:  N Hirji; M Griffiths
Journal:  Eye (Lond)       Date:  2012-08-10       Impact factor: 3.775

4.  Mitomycin C: a promising agent for the treatment of canine corneal scarring.

Authors:  Rangan Gupta; Benjamin W Yarnall; Elizabeth A Giuliano; Jagat R Kanwar; Dylan G Buss; Rajiv R Mohan
Journal:  Vet Ophthalmol       Date:  2011-04-18       Impact factor: 1.644

5.  Mitomycin against posterior capsular opacification: an experimental study in rabbits.

Authors:  C M Haus; A L Galand
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

6.  Tocotrienol inhibits proliferation of human Tenon's fibroblasts in vitro: a comparative study with vitamin E forms and mitomycin C.

Authors:  Alexander Meyenberg; David Goldblum; Jean-Marc Zingg; Angelo Azzi; Kalanithi Nesaretnam; Monika Kilchenmann; Beatrice E Frueh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-21       Impact factor: 3.117

7.  Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells.

Authors:  Masahiko Ayaki; Atsuo Iwasawa; Yoichi Inoue
Journal:  Clin Ophthalmol       Date:  2010-10-21

8.  Occlusion of the retinal vasculature after trabeculectomy with mitomycin C.

Authors:  R M Nuyts; H A Van Diemen; E L Greve
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

9.  Detection of corneal fibrosis by imaging second harmonic-generated signals in rabbit corneas treated with mitomycin C after excimer laser surface ablation.

Authors:  Marjan Farid; Naoyuki Morishige; Larry Lam; Andrew Wahlert; Roger F Steinert; James V Jester
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-23       Impact factor: 4.799

10.  Antifibrotic effects of tocotrienols on human Tenon's fibroblasts.

Authors:  Christoph Tappeiner; Alexander Meyenberg; David Goldblum; Daniel Mojon; Jean-Marc Zingg; Kalanithi Nesaretnam; Monika Kilchenmann; Beatrice E Frueh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-14       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.